Viracta, NantKwest deal

Viracta granted NantKwest exclusive, worldwide rights to develop and commercialize VRx-3996 in combination with its portfolio of natural killer (NK) cell therapies. Viracta is eligible for development and commercial milestones plus royalties. Viracta said it retains rights to the histone deacetylase (HDAC) inhibitor outside of its use with non-NK cells. The companies declined to disclose financial details...